Hemostatic Disorder of Uremia: The Platelet Defect, Main Determinant of the Prolonged Bleeding Time, Is Correlated with Indices of Activation of Coagulation and Fibrinolysis

Summary

Several parameters of primary hemostasis and markers of activation of coagulation and fibrinolysis were measured in 48 patients with severe (creatinine clearance <20 ml/min) chronic renal failure (CRF) without dialysis and diseases or drugs affecting hemostasis. Bleeding time (BT) was prolonged in 25/48 patients, and was correlated with age of patients, severity of renal failure, hematocrit, impairment in platelet aggregation-secretion and decrease in platelet ATP content. Defects in von Willebrand factor played no role in the prolongation of the BT. Multivariate analysis showed that only platelet dysfunction and severity of renal disease were independent predictors of the BT in uremia. The platelet functional disorder was significantly correlated with a reduction in platelet ATP and ADP.

High levels of plasma thrombin-antithrombin complexes (TAT), prothrombin fragment F₁₊₂, fibrinogen and factor VIIc were observed in patients with CRF, as described in prethrombotic states. Plasmin-antiplasmin complexes (PAP), fibrinogen and fibrin degradation products (FgDP, FnDP) were significantly increased, and the activity of plasminogen activator inhibitor (PAI-1) was slightly reduced, denoting an activation of fibrinolysis.

A negative correlation was found between platelet levels of ATP and ADP with plasma TAT, F₁₊₂ and PAP. Furthermore, plasma PAI-1 activity was negatively correlated with the BT and was lower in patients with prolonged BT as compared with controls and patients with normal BT. These links between primary hemostasis and activation of coagulation and fibrinolysis suggest that increased intravascular generation of thrombin and/or plasmin is an important mediator of the defects in primary hemostasis, prolongation of the BT and, probably, bleeding in CRF.

• References

• 1 Remuzzi G. Bleeding in renal failure. Lancet 1988; i 1205-1208
• 2 Gordge MP, Neild GH. Platelet function in uremia. Platelets 1991; 2: 115-123
• 3 Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46: 287-296
• 4 Steiner RW, Coggins C, Carvalho ACA. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7: 107-117
• 5 Gordge MP, Faint RW, Rylance PB, Neild GH. Platelet function and the bleeding time in progressive renal failure. Thromb Haemost 1988; 60: 83-87
• 6 Livio M, Gotti E, Marchesi D, Mecca G, Remuzzi G, de Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 1982; 1013-1015
• 7 Fernandez F, Goudable C, Sie P, Ton-That H, Durand D, Sue JM, Boneu B. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985; 59: 139-148
• 8 Castillo R, Lozano T, Escolar G, Revert L, Lopez J, Ordinas A. Defective platelet adhesion on vessel subendothelium in uremic platelets. Blood 1986; 68: 337-342
• 9 Zwaginga JJ, Ijsseldijt JW, Beeser-Visser N, de Groot ph G, Vos J, Sixma JJ. High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. Blood 1990; 75: 1498-1508
• 10 Escolar G, Cases A, Bastida E, Garrido M, Lopez J, Revert L, Castillo R, Ordinas A. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein Ilb-IIIa. Blood 1990; 76: 1336-1340
• 11 Castaldi PA, Rozenberg MC, Stewart JH. The bleeding disorder of uraemia. Lancet 1966; 66-69
• 12 Di Minno G, Martinez J, McKean M, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis Am J Med 1985; 79: 552-559
• 13 Kyrle PA, Stockenhuber F, Brenner B, Gossinger H, Kominger C, Pabinger I, Sunder-Plassmann G, Balcke P, Lechner K. Evidence for an increased generation of prostacyclin in the microvasculature and an impairment of the platelet alfa-granule release in chronic renal failure. Thromb Haemost 1988; 60: 205-208
• 14 Soslau G, Brodsky I, Putatunda B, Parker J, Schwartz AB. Selective reduction of serotonin storage and ATP release in chronic renal failure patient platelets. Am J Hematol 1990; 35: 171-178
• 15 Gralnick HR, McKeown LP, Williams SB, Shafer BC, Pierce L. Plasma and platelet von Willebrand factor defects in uremia. Am J Med 1988; 85: 806-810
• 16 Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701
• 17 Tomura S, Nakamura Y, Deguchi F, Ando R, Chida Y, Marumo F. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Thromb Res 1991; 64: 81-90
• 18 Sagripanti A, Cupisti A, Baicchi U, Ferdeghini M, Morelli E, Barsotti G. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993; 63: 273-278
• 19 Boisclair MD, Lane DA, Ireland H, Philippou H, Esnouf P. Proteinase cascade activation in human renal failure. Impaired proteinase regulation in haemodialysis as a mechanism for thrombogenesis. Thromb Haemost 1993; 69: 778A
• 20 Panicucci F, Sagripanti A, Pinori E, Vispi M, Lecchini L, Barsotti G, Giovannetti S. Comprehensive study of haemostasis in chronic uraemia. Nephron 1983; 33: 5-8
• 21 Vaziri ND, Shah GM, Winer RL, Gonzales E, Patel B, Alikhani S, Nguyen QX, Yamamoto J. Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis. Thromb Res 1989; 53: 173-180
• 22 Gris J-C, Branger B, Vecina F, Sabadini BA, Fourcade J, Schved J-F. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994; 46: 807-813
• 23 Canavese C, Stratta P, Pacitti A, Mangiarotti G, Racca M, Oneglio R, Ver-cellone A. Impaired fibrinolysis in uremia: partial and variable correction by four different dialysis regimes. Clin Nephrol 1982; 17: 82-89
• 24 Hong SY, Yang DH. Fibrinolytic activity in end-stage renal disease. Nephron 1993; 63: 188-192
• 25 Brommer EJP, Schicht I, Wijngaards G, Verheijen JH, Rijken DC. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients. Thromb Haemost 1984; 52: 311-314
• 26 Nakamura Y, Chida Y, Tomura S. Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment. Nephron 1991; 58: 201-204
• 27 Gordge MP, Faint RW, Rylance PB, Ireland H, Lane DA, Neild GH. Plasma D dimer: a useful marker of fibrin breakdown in renal failure. Thromb Haemost 1989; 61: 522-525
• 28 Pasche B, Loscalzo J. Platelets and fibrinolysis. Platelets 1991; 2: 125-134
• 29 Hamilton KK, Fretto LJ, Grierson DS, McKee PA. Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation and release in vivo. J Clin Invest 1985; 76: 261-270
• 30 Holmsen H, Dangelmaier CA. Measurement of secretion of serotonin. In: “Methods in Enzymology” Vol 169,1989 Jacek Hawiger. ed. Chapter 17, pp 205-210
• 31 Holmsen H, Dangelmaier CA. Measurement of secretion of adenine nucleotides. In: “Methods in Enzymology” Vol 169, 1989 Jacek Hawiger. ed. Chapter 16, pp 195-205
• 32 Drummond AH, Gordon JL. Rapid, sensitive microassay for platelet 5-HT. Thrombos Diath Haemorrh 1974; 31: 366-367
• 33 Patscheke H. Shape and functional properties of human platelets washed with acid citrate. Haemostasis 1981; 10: 14-27
• 34 Markwell MAK, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipotrotein samples. Anal Biochem 1978; 87: 206-210
• 35 Kristopeit SM, Kunicki TJ. Quantitation of platelet membrane glycoproteins in Glanzmann’s thrombastenia and the Bemard-Soulier syndrome by electroimmunoassay. Thromb Res 1984; 36: 133-142
• 36 LoBuglio AF, Court WS, Vinocur L, Maglott G, Shaw GM. Immune thrombocytopenic purpura. Use of a 1251-labeled monoclonal antibody to quantify platelet-bound IgG. N Engl J Med 1983; 309: 459-463
• 37 Steinberg MI, Kelton JG, Coller BS. Plasma glycocalicin, am aid in the classification of thrombocytopenic disorders. N Engl J Med 1987; 317: 1037-1042
• 38 Ledford MR, Kent JW, Civantos F. A comparative study of three methods for the visualization of von Willebrand factor (vWF) multimers. Thromb Haemost 1990; 64: 569-575
• 39 Shattil SJ, Bennett JS. Acquired qualitative platelet disorders due to diseases, drugs, and foods. In: “Williams Hematology”. Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. McGraw-Hill, New York 1995, Chapter 133, pp 1386-1400
• 40 Kamoun P, Kleinknecht D, Ducrot H, Jerome H. Platelet serotonin in uremia. Lancet 1970; 782
• 41 Eknoyan G, Brown CH. Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. Am J Nephrol 1981; 1: 17-23
• 42 Sloand EM, Sloand JA, Prodouz K, Klein HG, Yu MW, Harvath L, Fricke W. Reduction of platelet glycoprotein lb in uraemia. Br J Haematol 1991; 77: 375-381
• 43 Michelson AD, Barnard MR. Plasmin-induced redistribution of platelet glycoprotein lb. Blood 1990; 76: 2005-2010
• 44 Benigni A, Boccardo P, Galbusera M, Monteagudo J, De Marco L, Remuzzi G, Ruggeri ZM. Reversible activation of the platelet glycoprotein Ilb-IIIa complex in patients with uremia. Am J Kidney Dis 1993; 22: 668-676
• 45 Castaman G, Rodeghiero F, Lattuada A, La Greca G, Mannucci PM. Multimeric pattern of plasma and platelet von Willebrand factor is normal in uremic patients. Am J Hematol 1993; 44: 266-269
• 46 Rodgers RPC, Levin J. A critical reappraisal of the bleeding time. Sem Thromb Hemostas 1990; 16: 1-20
• 47 Walkowiak B, Pawlowska Z, Michalak E, Ciemiewski CS. Expression of fibrinogen receptors on platelets of uremic patients is correlated with the content of GPIIb and plasma level of creatinine. Thromb Haemost 1994; 71: 164-168
• 48 Handagama P, Scarborough RM, Shuman MA, Bainton DF. Endocytosis of fibrinogen into megakaryocyte and platelet alpha granules is mediated by alphaIIbP3 (glycoprotein Ilb-IIIa). Blood 1993; 82: 135-138
• 49 III CR, Ruoslahti E. Association of thrombin-antithrombin III complex with vitronectin in serum. J Biol Chem 1985; 260: 15610-15615
• 50 Shifman MA, Pizzo SV. The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem 1982; 257: 3243-3248
• 51 Savion N, Farzame N. Binding uptake and degradation of antithrombin Ill-protease complexes by cultured corneal endothelial cells. Exp Cell Res 1984; 153: 50-60
• 52 Sorensen JV, Jensen HP, Rahr HB, Borris LC, Lassen MR, Knudsen F. F1+2 and FpA in urine from patients with multiple trauma and healthy individuals. A pilot study. Thromb Res 1992; 67: 429-434
• 53 Hultin MB. Fibrinogen and factor VII as risk factors in vascular disease. In: “Progress in Hemostasis and Thrombosis44. Coller BS, ed. W. B. Saunders Co, Philadelphia, 1991 10. 215-241
• 54 Wing LR, Combe CJ, Bennett B, Booth NA. A receptor in primary human hepatocytes fort-PA-PAI-1 and plasmin-alpha2-antiplasmin complexes. Br J Haematol 1992; 80 (Suppl. 01) Suppl 5(A)
• 55 Gonias SL, Fuchs HE, Pizzo SV. A unique pathway for the plasma elimination of alpha2-antiplasmin-protease complexes in mice. Thromb Haemost 1982; 48: 208-210
• 56 Nakamura Y, Tomura S, Tachibana K, Chida Y, Marumo F. Enhanced fibrinolytic activity during the course of hemodialysis. Clin Nephrol 1992; 38: 90-96
• 57 Hong SY, Yang DH. Insulin levels and fibrinolytic activity in patients with end-stage renal disease. Nephron 1994; 68: 329-333
• 58 Takagi M, Wada H, Mukai K, Kihira H, Yano S, Minamikawa K, Wakita Y, Nakase T, Nagaya S, Deguchi K, Shirakawa S, Suzuki K. Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance haemodialysis. Blood Coag Fibrinolysis 1994; 5: 713-717
• 59 Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alfa. Kidney Int 1990; 37: 116-125
• 60 Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-16, TNFalpha and their specific inhibitors in un-dialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890-896
• 61 van Deventer SJH, Biiller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526
• 62 Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Biiller HR, van Deventer SJH, Hack CE, ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120
• 63 Levine JD, Harlan JM, Harker LA, Joseph ML, Counts RB. Thrombin-mediated release of Factor VIII antigen from human umbilical vein endothelial cells in culture. Blood 1982; 60: 531-534
• 64 Levin EG, Marzec U, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 1984; 74: 1988-1995
• 65 Ribes JA, Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest 1987; 79: 117-123
• 66 van Hinsbergh VWM, Vermeer M, Koolwijk P, Grimbergen J, Kooistra T. Genistein reduces tumor necrosis factor alfa-induced plasminogen activator inhibitor 1 transcription but not urokinase-type expression in human endothelial cells. Blood 1984; 84: 2984-2991
• 67 Brass LF. Molecular basis for platelet activation. In “Hematology. Basic Principles and Practice”. Hoffman R, Benz Jr. EJ, Shattil SJ, Furie B, Cohen HJ, Silverstein LE, eds. Churchill Livingstone, New York, 1995. Chapter 98, pp 1536-1552
• 68 Reimers H-J, Kinlough-Rathbone RL, Cazenave J-P, Senyi AF, Hirsh J, Packham MA, Mustard JF. In vitro and in vivo functions of thrombin-treated platelets. Thromb Haemost 1976; 35: 151-166
• 69 Shuman MA, Botney M, Fenton II JW. Thrombin-induced platelet secretion. Further evidence for a specific pathway. J Clin Invest 1979; 63: 1211-1218
• 70 Holme S, Holmsen H. ADP-induced refractory state of platelets in vitro. I. Methodological studies on aggregation in platelet rich plasma. Scand J Haematol 1975; 15: 96
• 71 Remuzzi G, Cavenaghi AE, Mecca G, Donati MB, de Gaetano G. Prostacyclin-like activity and bleeding in renal failure. Lancet 1977; 1195-1197
• 72 Noris M, Benigni A, Boccardo P, Aiello S, Gaspari F, Todeschini M, Figli-uzzi M, Remuzzi G. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Intemat 1993; 44: 445-450
• 73 Vlacoyannis J, Schoeppe W. Adenylate cyclase activity and cAMP content of human platelets in uremia. Eur J Clin Invest 1982; 12: 379-381
• 74 Jacobsson B, Ransnas L, Nyberg G, Bergh C-H, Magnusson Y, Hjalmar-zon A. Abnormality of adenylate cyclase regulation in human platelet membranes in renal insufficiency. Eur J Clin Invest 1985; 15: 75-81
• 75 Weinstein MJ, Chute LE, Schmitt GW, Hamburger RH, Bauer KA, Troll JH, Janson P, Deykin D. Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation. J Clin Invest 1985; 76: 1406-1411
• 76 Penny WF, Ware JA. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator. Blood 1992; 79: 91-98
• 77 Schafer AI, Adelman B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest 1985; 75: 456-461
• 78 Di Minno G, Cerbone A, Usberti M, Cianciaruso B, Cortese A, Farace MJ, Martinez J, Murphy S. Platelet dysfunction in uremia. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med 1986; 108: 246-252
• 79 Pasche B, Ouimet H, Francis S, Loscalzo J. Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 1994; 83: 404-414
• 80 Pasqua JJ, Pizzo SV. The role of ligand-ligand interactions in competition by fibrinogen and fibrin degradation products for fibrinogen binding to normal platelets. Biochem Biophys Acta 1983; 757: 282-287
• 81 Culasso DE, Donati MB, de Gaetano G, Vermylen J, Verstraete M. Inhibition of human platelet aggregation by plasmin digests of human and bovine fibrinogen preparations: role of contaminating factor VUI-related material. Blood 1974; 44: 169-175
• 82 Booth NA. The natural inhibitors of fibrinolysis. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham AGD, eds. Churchill Livingstone, Edinburgh, 3rd Ed, 1994, Chapter 31, pp 699-717
• 83 Fay W, Shapiro A, Shih J, Schleef R, Ginsburg D. A frameshift mutation resulting in complete plasminogen activator inhibitor-1 (PAI-1) deficiency. N Engl J Med 1992; 327: 1729-1733
• 84 Williams EC. Disseminated intravascular coagulation. In: “Thrombosis and Hemorrhage”. Loscalzo J, Schafer AI, eds. Blackwell Scientific Publ, Cambridge, 1994, Ch. 46, pp 921-943